Daewon Pharmaceutical's P-CAB Drug Succeeds in Phase 3 Trial... Plans Approval Application This Year
For 328 Patients With Gastroesophageal Reflux Disease
Demonstrates Non-Inferiority to Existing Treatment
Daewon Pharmaceutical's novel treatment for gastroesophageal reflux disease, Padoprazan (DW4421), a potassium-competitive acid blocker (P-CAB), met the primary efficacy endpoint in a domestic Phase 3 clinical trial.
According to Daewon Pharmaceutical on October 29, the Phase 3 trial was conducted to evaluate the efficacy and safety of Padoprazan in patients with erosive gastroesophageal reflux disease (ERD). A total of 328 patients at 22 medical institutions in South Korea were enrolled, and the Padoprazan 20 mg and 40 mg groups were compared with a group receiving 40 mg of esomeprazole, an existing proton pump inhibitor (PPI).
The primary efficacy endpoint was complete healing of esophageal mucosal defects confirmed by endoscopy. The trial assessed whether the lower bound of the two-sided 95% confidence interval for the difference in efficacy rates between the Padoprazan and esomeprazole groups exceeded the prespecified non-inferiority margin of -10.0%.
The results showed that the 95% confidence interval for the difference in efficacy rates between the Padoprazan 40 mg group and the control group was -2.50% to 6.87%, while that for the 20 mg group was -3.90% to 6.58%. The lower bounds for both doses met the non-inferiority criterion, demonstrating non-inferiority to esomeprazole.
The incidence of adverse drug reactions was 4.59% in the Padoprazan 40 mg group, 3.74% in the 20 mg group, and 3.70% in the esomeprazole group. There was no statistically significant difference in incidence rates among the groups, and no serious adverse events occurred.
Based on these topline results, Daewon Pharmaceutical plans to conduct detailed analyses of efficacy and safety, submit the final clinical study report to the Ministry of Food and Drug Safety within the year, and apply for product approval. A Phase 3 trial in patients with non-erosive gastroesophageal reflux disease (NERD) is also underway, and the company is preparing clinical trials to obtain additional indications.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Daewon Pharmaceutical official said, "We will proceed with detailed analyses and the product approval process without delay, and work to provide patients with gastroesophageal reflux disease with a new treatment option."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.